Featuring perspectives from Dr Jacob Laubach, including the following topics:
- Evolution of first-line treatment for multiple myeloma (MM) (0:00)
- Perspectives on the future of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapy for the management of MM (13:27)
- ASH 2022 updates on front-line management of MM for transplant-ineligible patients (18:35)
- ASH 2022 updates on the use of isatuximab-containing regimens for newly diagnosed and relapsed/refractory (R/R) MM (24:57)
- ASH 2022 updates on the clinical efficacy of CAR T-cell therapy for R/R MM; perspectives on the future of belantamab mafodotin (35:05)
- ASH 2022 updates on the efficacy and safety of teclistamab for R/R MM (46:33)
- Bispecific antibody therapy administration and patient education (52:41)
- ASH 2022 updates on investigational bispecific antibodies and other novel therapies for MM (1:00:17)
CME information and select publications
Research To Practice | Oncology Videos